Moreover, molecular subtyping has gained attention in recent years, particularly with the classification of lesions into hormone receptor-positive (ER+/PR+), HER2-positive, and triple-negative breast cancer (TNBC)22. This evidence concerns the gene PGR and triple-negative breast carcinoma.